Business Wire

MARIA-MIDDELARES

Share
World First at Maria Middelares Hospital in Belgium Thanks to da Vinci SP’s Innovative Technology

As part of the new Health Value Space Ghent, Maria Middelares Hospital continues to lead the way as a “smart” hospital, poised to deliver healthcare of the future to its patients. The new da Vinci SP (single port) surgical system has now been in use since May 21, making complex surgery even less invasive, via a single incision. It was on May 27 that a world first took place at the hospital: a kidney autotransplantation assisted by the da Vinci SP surgical system.

The arrival of Intuitive’s new da Vinci SP system aligns perfectly with Maria Middelares' vision of developing a patient-oriented robotics platform. The SP enables more complex procedures to be performed through a single incision or natural orifice. Over 400 peer-reviewed publications demonstrate the safety, efficacy, and excellent results of this cutting-edge technology. The da Vinci SP offers incredible value on a daily basis for Maria Middelares and its patients.

  • A World First

On May 27, urologist Prof. dr. Decaestecker achieved a world first. Using the da Vinci SP, he performed an intracorporeal kidney autotransplantation on an 18-year-old woman suffering from a complex ureteral lesion, with severe damage to the ureter between the kidney and the bladder. The best solution for the patient was to bridge the major defect in the ureter by moving the kidney closer to the bladder. This technique is called autotransplantation.

The transplantation was achieved intracorporeally, meaning entirely inside the body. Prof. dr. Decaestecker has perfected this technique, having performed such operations since 2017 (a European first at the time) using the da Vinci Multiport system, equipped with four robotic arms. The advantage of an in-body operation is that no large incisions are required to move the kidney in and out of the body; only a few small incisions (with the Multiport) of around 1 cm were needed to introduce the robotic instruments.

Prof. dr. Decaestecker explains: What’s new now is the combination of in-body grafting with a single incision thanks to the SP robotic system, which has just one articulated arm. This is less intrusive for the patient’s body and should also facilitate smoother post-op recovery. Other advantages are that we can perform the procedure entirely outside the abdomen, allowing the patient to lie flat on their back in a natural position. This is important as the patient can now be operated on in a more comfortable position, therefore with fewer intestinal complications.”

  • What does the future hold?

With the development of a robotics platform, Maria Middelares aims to optimize the use of robotic systems within the operating room as much as possible. The goal is to improve operating room efficiency and patient outcomes. These innovative surgical systems allow for further personalization of surgery based on patient needs.

Dr. Ameye, Director of Innovation, adds: “In our organization, we strive to seek out the best technology combined with in-depth monitoring. We map the quality of care using big data analysis based on a multitude of uniform data. This enables us to identify areas for improvement and continuously optimize our care. Providing value-based healthcare is our main motivation.”

You can download images from the operating room of this world premiere via this link.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240529830425/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press release

Ranks 125th Among 500 Companies Around the GlobeTop 10% in the Environmental Sector Among 3,000 Major Global Companies Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 10

Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release

The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa

ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release

Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai

Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye